Kahira Pharmaceuticals and Chemical Industries Co

Kahira Pharmaceuticals maintains a conservative capital structure with a debt-to-equity ratio of 0.34, indicating a relatively low reliance on debt financing. The company's liquidity position is characterized as medium risk, with a current ratio of 2.2, suggesting it can cover its short-term obligations but with limited excess capacity. Free cash flow of EGP 247.36 million indicates strong cash generation, though capital expenditures of EGP 168.47 million suggest ongoing investment in infrastructure or production capacity.

Profitability metrics show a return on equity of 9.47% and a return on assets of 4.82%, which are to be compared against industry benchmarks for pharmaceutical firms. These figures suggest Kahira is generating returns above the typical cost of capital, though the ROA is moderate, indicating room for improvement in asset utilization.

Geographic and segment exposure is not explicitly detailed in the available data, but as a domestic Egyptian firm, Kahira's revenue is likely concentrated within the local market. The absence of international revenue breakdowns or segment-specific financials limits the ability to assess diversification risk.

Growth trajectory is supported by a strong operating cash flow of EGP 119.40 million and a net income of EGP 74.55 million. However, the company's future growth will depend on its ability to maintain or expand its market share in a competitive domestic pharmaceutical landscape.

Risk factors include a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could constrain its ability to fund new initiatives without external financing. No dilution risk is currently flagged, and no adjustments have been applied to the valuation metrics.

Recent events or filings are not detailed in the provided data, but the company's financial health appears stable with no immediate signs of distress. Continued monitoring of capital expenditures and debt management will be important for assessing long-term sustainability.

Revenue surged 52.8% year-over-year to EGP 2.08 billion, demonstrating strong top-line growth momentum.

Net income expanded 80.3% to EGP 443.7 million, significantly outpacing revenue growth rates.

Free cash flow turned positive at EGP 119.5 million, reversing previous negative trends.

Long-term debt increased to EGP 221.8 million, reflecting a rising leverage profile.

Debt-to-equity ratio of 0.34 is higher than the cohort median of 0.18.

The company faces medium liquidity risk, potentially impacting short-term financial flexibility.

Medium credit risk flags suggest potential challenges in maintaining optimal borrowing costs.

Revenue EGP 1.36B, +35,4% YoY; Operating income +270,7% YoY.

• ▍Revenue EGP 1.36B, +35,4% YoY
• ▍Operating income +270,7% YoY
• ▍Net income +153,5% YoY
• ▍Free cash flow +5,3% YoY
• ▍Net margin 18.1%

Revenue EGP 1.01B, −9,6% YoY; Operating income −54,7% YoY.

• ▍Revenue EGP 1.01B, −9,6% YoY
• ▍Operating income −54,7% YoY
• ▍Net income −41,4% YoY
• ▍Free cash flow −180,6% YoY
• ▍Net margin 9.7%

Revenue EGP 1.11B, +4,7% YoY; Operating income +27,2% YoY.

• ▍Revenue EGP 1.11B, +4,7% YoY
• ▍Operating income +27,2% YoY
• ▍Net income +33,3% YoY
• ▍Free cash flow +278,8% YoY
• ▍Net margin 14.9%

Revenue EGP 1.06B; Operating income EGP 173.7M.

• ▍Revenue EGP 1.06B
• ▍Operating income EGP 173.7M
• ▍Net margin 11.7%